Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$465.70 USD

465.70
2,581,339

-18.26 (-3.77%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $466.69 +0.99 (0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Balance Sheet

Research for VRTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Vertex Pharmaceuticals Incorporated falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 11,218 10,779 7,525 6,659 3,808
Receivables 1,563 1,442 1,137 885 634
Notes Receivable 0 0 0 0 0
Inventories 739 461 353 281 168
Other Current Assets 624 554 546 308 214
Total Current Assets 14,144 13,235 9,561 8,133 4,823
Net Property & Equipment 1,159 1,108 1,094 959 745
Investments & Advances 2,498 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 1,812 1,247 935 883 1,191
Intangibles 1,928 1,692 1,402 1,402 1,402
Deposits & Other Assets 895 522 111 49 158
Total Assets 22,730 18,151 13,433 11,752 8,318
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 365 304 195 155 88
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 2,655 2,127 1,679 1,405 1,117
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 527 312 268 317 130
Total Current Liabilities 3,547 2,742 2,142 1,878 1,335
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 376 431 510 539 539
Other Non-Current Liabilities 878 686 303 298 360
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 5,150 4,238 3,333 3,065 2,233
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 3 3 3 3 3
Capital Surplus 7,450 7,387 6,881 7,894 7,938
Retained Earnings 10,142 6,523 3,201 859 -1,853
Other Equity -14 1 16 -68 -2
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 17,580 13,913 10,100 8,687 6,085
Total Liabilities & Shareholder's Equity 22,730 18,151 13,433 11,752 8,318
Total Common Equity 17,580 13,913 10,100 8,687 6,085
Shares Outstanding 257.60 256.60 254.20 260.00 257.10
Book Value Per Share 68.25 54.22 39.73 33.41 23.67

Fiscal Year End for Vertex Pharmaceuticals Incorporated falls in the month of December.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents 6,525 5,796 10,171 11,218 11,928
Receivables 1,751 1,656 1,793 1,563 1,539
Notes Receivable 0 0 0 0 0
Inventories 1,080 915 813 739 689
Other Current Assets 449 575 511 624 540
Total Current Assets 9,804 8,942 13,289 14,144 14,696
Net Property & Equipment 1,118 1,201 1,173 1,159 1,124
Investments & Advances 4,704 4,393 4,381 2,498 1,700
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 2,309 2,186 1,963 1,812 1,729
Intangibles 1,920 1,926 1,923 1,928 1,692
Deposits & Other Assets 990 916 876 895 475
Total Assets 22,240 20,132 23,917 22,730 21,726
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 396 328 351 365 376
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 3,220 2,940 2,796 2,655 2,907
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 358 279 649 527 316
Total Current Liabilities 3,973 3,547 3,796 3,547 3,599
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 114 347 362 376 390
Other Non-Current Liabilities 933 854 878 869
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 6,609 5,357 5,371 5,150 5,213
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 3 3 3 3 3
Capital Surplus 6,906 7,101 7,285 7,450 7,340
Retained Earnings 8,694 7,648 11,242 10,142 9,174
Other Equity 29 23 17 -14 -3
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 15,631 14,775 18,547 17,580 16,513
Total Liabilities & Shareholder's Equity 22,240 20,132 23,917 22,730 21,726
Total Common Equity 15,631 14,775 18,547 17,580 16,513
Shares Outstanding 258.10 258.00 258.40 257.60 258.10
Book Value Per Share 60.56 57.27 71.77 68.25 63.98